We consult with every patient to ensure that semaglutide is the right medication for them
Contraindications Do not use DSIP if you: Are pregnant or breastfeeding (insufficient safety data) Have sleep apnea or other breathing-related sleep disorders (sedation risk) Take prescription sedatives or sleep medications Have a history of severe reactions to injected peptides Are under 18 years old If you have any chronic medical condition or take regular medications, consult a healthcare provider familiar with peptide therapies before starting DSIP
Key Challenges Absorption Issues Glutathione breaks down in the gut, so liposomal, transdermal, or IV routes may be more effective
Semaglutide is also approved as Ozempic and Rybelsus for lowering blood sugar in diabetes, but only Wegovy is approved for chronic weight management
These findings lay a groundwork for future research to explore the specific causal pathways and develop targeted therapeutic interventions
Never hesitate to report new or worsening symptomsearly intervention can prevent complications and optimise your diabetes management